Beyond Embryonic Stem Cells

Learn how a community is successfully pursuing health information exchange, interoperability and meaningful use across small and medium practices, hospitals and facilities using a combination of tools, guidance and incentives. This "Roadmap to Meaningful Use" program helps providers realize the quality, efficiency and financial incentives promised in the ARRA Stimulus funding.

All great ideas sound “insane” at first. This presentation will describe three insane ideas that Ovum believes will transform healthcare in the future including:
• Telehealth is for everyone, not just the elderly.
• Patient self-diagnosis is good and should be promoted.
• Personal health records are not just a passing trend, they are the solution.

Electronic health records may generate a new set of potential healthcare compliance risks and vulnerabilities. The new risk areas, including, the lack of authentication issues, over-documentation and/or cloning, may have significant ramifications beyond billing and coding. Electronic documentation tools offer exciting features designed to enhance communication for most health record users. The use of the system or specific features without appropriate education, training, infrastructure and monitoring may generate data integrity issues, manufactured documentation, increased risk exposure or even undesirable clinical outcomes. This presentation addresses certain areas of concern and discusses potential approaches for detection, evaluation and corrective action.

When I tried to move my health data from my hospital to Google Health, what happened was front page news; the transfer was so bad it was covered by the Information Quality Trainwrecks blog. But that doesn't change my conviction one bit: Good quality data, well managed, can vastly empower the new world of doctor-patient collaboration known as Participatory Medicine.

As an empowered e-patient, a business process analyst and a day-job data geek, in this talk I'll lay out the Society's vision for the role a good EHR can play in creating more efficient - and more effective - healthcare, in ways that benefit providers and patients alike.

Clinical groupware is a new and evolving model for the development and deployment of health information technology (HIT) platforms and applications having the following characteristics:
Use of the Internet and the web for EHR technology.
Explicit design for information sharing and online communication among providers and patients/consumers.
A modular or component architecture upon which applications can be aggregated to meet specific clinical and workflow tasks.
Patient/consumer engagement tools that facilitate ongoing health management and care coordination.
Interface and data exchange standards for information sharing that emerge in a market-driven manner.
The Clinical Groupware Collaborative is in a formative stage organization. To date, representatives from over 50 companies have expressed interest. We are working to be formally incorporated in November 2009.

New HIPAA Rules and EHRs: ARRA & Breach Notification

Business Associates first made their appearance in the HIPAA regulations almost a decade ago. During the first few years under the HIPAA regulations business associates used PHI of a HIPAA covered entity to do work for the covered entity including claims processing, data analysis, utilization review, benefit management, and practice management. In other words, the work was in the areas of administration, payment and health care operations. This electronic data sharing was between no more than two or three entities.

The world has advanced and we now have Electronic Health Records (EHRs), Personal Health Records (PHRs), Regional Health Information Organizations (RHIOs) and Health Information Interchanges (HIEs) that share clinical information electronically. This data sharing is among a much larger universe, among many more entities, through much different technologies.

Until the HITECH Act PHRs, RHIOs and HIEs were not business associates. Business associates now include these new forms of clinical data repositories and sharing organizations and must keep most of the HIPAA privacy and security requirements as if they are covered entities and not just through a contract, a business associate agreement with a covered entity.

This session will outline the new world of business associates in clinical information sharing.

There is increasing interest in the United States and abroad in implementing electronic health records as part of an effort to improve the process, cost, and outcomes of health care. Kaiser Permanente has been working toward a goal of automating all health information on its 8.6 million members. Work began, in some ways more than 30 years ago. With focus on a vision for health care in the 21st century, our Kaiser Permanente HealthConnect® electronic health record has been fully deployed in all of our 431 medical offices, and 33 of our 36 hospitals (the remainder will be completed in the first quarter of 2010). We have also deployed a personal health record actively used by more than 3 million members. Along the way to this success, we have made mistakes and learned many hard lessons. The presentation will share that experience and describe some of the benefits of the system.

This panel, moderated by David Maizenberg, will feature former Division Director at FDA and 30 year biopharma veteran, Max Talbott, Joanna Napp, Healthcare and IP partner at Jackson Walker, and health care law expert Jeffery Drummond. The discussion will cover FDA regulation of Internet-based communications by biopharmaceutical companies, starting with the recent keyword advertising warning letters and subsequent draft regulations. The panel will also delve into possible scenarios for biopharmaceutical company participation in conversational and social media: the next frontier for communications with doctors, patients and wider communities of interest.

The patent system is based on a social contract between the inventor and the state. In return for a disclosure of the invention by the inventor, the state grants the inventor or his assignee a period in which he can exclude others from using his or her invention. The two sides of this contract are reflected in the two principle parts of a patent:1) the description of the invention and how to put it into practice and 2) the claims or definition of the invention which determine who one can sue for trespassing onto one's invention. In recent years the courts have placed increased emphasis on trying to establish a proper balance between the contribution made by the description and the permissible breadth of the definition set out in the claims. Different countries can take different views as to where the balance point should lie. In today's global marketplace, such differences can be very important.

In this presentation we will look at how pharmaceutical inventions may be defined and the requirements of the disclosure in order to support such definitions with particular emphasis on issues that arise as one moves from an appreciation of the significance of a new biochemical discovery to using that discovery as a basis for treatment. If one files a patent application too early with insufficient disclosure the courts may conclude that one is merely speculating and not entitled to a patent because "the invention" has not yet been made. If one waits too long, noe may lose the race to the patent office. The presentation will try to untangle the issues involved.

Open Notebook Science for Collaborative Drug Discovery

The current business model for biotech and pharmaceutical companies is broken. Every aspect of R&D has changed over the last 20 years, yet analysis of the industry is still based on oversimplified models. As a result of this global financial crisis, the impact of reduced research budgets of pharmaceutical and biotech companies will be played out for the next 3-5 years. There is a need to develop new therapeutics and appropriate business models that clearly demonstrate the compelling value to invest in, and develop, new therapeutics. Four compelling reasons challenging assumptions on investment and motivations discuss why walking the path less traveled could make all the difference. An opportunity exists; with new business models, collaboration across the industry and hard work, success can be exploited from this situation.

Understanding eHealth Sustainability in Developing Countries: The Five 'Is' Concept

This session will provide attendees with: an update on the CONNECT solution; an overview of how federal agencies are using the solution to tie into the Nationwide Health Information Network; and outline of the benefits that federal participation in the NHIN and will provide to patients, care providers, payers and other health stakeholders. This session will also detail citizen to citizen benefits that a nationwide network of interoperable health IT will provide, ranging from improved healthcare and faster benefits administration to quicker identification and response to public health emergencies.

Craig Miller

Miller is the chief architect for CONNECT, a SOA-based solution that connects federal agencies into nationwide health information exchanges. As a strategic advisor to the Federal Health Architecture (FHA) program, he guides the development of CONNECT and other federal solutions based on his expertise in electronic health information exchange, electronic health records and service-oriented architecture. Miller has more than 12 years of enterprise architecture experience at the director level, working with agencies such as HHS, CMS, FDA, USDA and OMB. He was the lead enterprise architect for HHS’ department-wide enterprise architecture initiative, and He led the development of versions 2.0-2.2 of the OMB EA Assessment Framework and was responsible for developing the structure of the Federal Transition Framework.

Too often hospital marketing or IT departments send off requests for proposals (RFPs) that list wanted functionally, and then wonder why their Web site vendor doesn't provide strategic value. The fact is, if you outsource some or part of your online initiatives, it's more important than ever that your vendor is proving their value. Join Geonetric as we help you look at your relationship with vendors in a strategic way, from RFP creation to ensuring continuous return on investment.

Please attend this Webinar if you want to learn more about:
- How to implement an effective process for selecting a Web partner
- What to include in an RFP to attract the right Web partners
- How to define Web goals and align them with what your Web partner is delivering
- How to develop long-term strategies with your vendor

The Future of Disease & Care Management for the Chronically Ill

Continua Health Alliance- paving the way for cost-effective standards-based telehealth solutions

Rick Cnossen
President and Chairman of the Board of Directors, Continua Health Alliance
Director, Personal Health Enabling
Intel Corporation Digital Health Group

Rick Cnossen is the president and chairman of the Board for the Continua Health Alliances. Continua is a large, international, cross-industry consortium, focused on the establishment of an eco-system of interoperable, personal telehealth systems. He is also a director of Personal Health Enabling for Intel’s Digital Health Group with a focus on medical device interoperability standards. Additionally, he serves on the HITSP Board of Directors and is a participating member of the ISO/IEEE 11073 Personal Health Data WG, the HITSP Consumer Perspectives Technical Committee, the Health Level Seven (HL7) Structured Document Technical Committee, the USB Personal Health Device WG, and the Bluetooth Medical Device Profile WG.

Mr. Cnossen holds a MSCS degree from the University of Southern California (USC). He worked at McDonnell Douglas (Boeing) for 15 years as a Software Engineering Manager on a variety of Aerospace and Defense projects and at Intel Corporation for 9 years as an Engineer Manager and Director. During this time, he has been involved in many industry technology and standards development efforts including Advanced Telecommunications Architecture (ATCA) Manageability Specification, Tactical Defense data collection / analysis, Hierarchical Data Assimilation and Storage, and High Performance Computing.

The increased pace of advances in science, technology, and healthcare and the need for medical breakthroughs have blurred the lines between traditional Biotechnology, Pharmaceutical Research, and Healthcare. Anyone who is familiar with these sectors knows that the data and information needs of these industries are large and complex and often daunting even within a single organization.
In this webcast, we will discuss implications of the patient data flow produced by each of these organizations. We will define what each of these types of organizations does in terms of their interaction with the patient and the data footprint that each of them generates. Further, we will outline trends in the context of each industry and what that might mean for the integration of data and systems. Finally, we will talk about the implications of interoperability within and between these sectors including the electronic and personal health record (EHR/PHR), health information exchanges (HIEs), the role of patient registries and epidemiology databases, and the converging data and interoperability standards (for example, CDISC, ICH, and HL7.)

At first glance, Federal stimulus funds from HITECH Act legislation appear to be a windfall for traditional electronic medical record 1.0 (EMR 1.0) technologies...

...but there's much more. HITECH is creating opportunities for disruptive technologies and new business models:
Platform/application technologies
Clinical groupware
Collaborative care management networks
Virtual integration

Learn about opportunities to deploy many new emerging technologies as part of HITECH, including PHRs, telehealth, secure patient/physician messaging, eRX, and many others. Collectively, these technologies will create a new business ecosystem for electronic health record 2.0 (EHR 2.0)